Broadcom Inc. R&D decreased by 0.5% to $2.97B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.6%, from $2.25B to $2.97B. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 22.6% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.24B | $1.21B | $1.20B | $1.21B | $1.26B | $1.26B | $1.20B | $1.20B | $1.31B | $1.36B | $1.39B | $2.31B | $2.42B | $2.35B | $2.23B | $2.25B | $2.69B | $3.05B | $2.98B | $2.97B |
| QoQ Change | — | -2.7% | -0.4% | +0.5% | +4.6% | -0.5% | -4.6% | -0.2% | +9.8% | +3.5% | +2.2% | +66.3% | +4.6% | -2.6% | -5.1% | +0.9% | +19.5% | +13.3% | -2.3% | -0.5% |
| YoY Change | — | — | — | — | +1.9% | +4.1% | -0.3% | -0.9% | +4.0% | +8.2% | +16.0% | +93.1% | +84.1% | +73.3% | +61.0% | -2.4% | +11.5% | +29.6% | +33.4% | +31.6% |